Meeting Overview - The fourth supervisory board meeting of Zhejiang Sandar Biopharmaceutical Co., Ltd. was held on July 7, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1][2]. Resolutions Passed - The supervisory board approved the proposal to use raised funds to replace pre-invested project funds and paid issuance expenses, with a unanimous vote of 3 in favor [1][2]. - The board also approved the proposal to provide loans from raised funds to the controlling subsidiary for project implementation, again with a unanimous vote of 3 in favor [2]. - A resolution was passed to manage idle raised funds for cash management purposes, receiving unanimous approval [2]. - The board approved the use of idle self-owned funds for cash management, also with unanimous support [2][3].

Core Viewpoint - The company has faced multiple delays in its fundraising project due to various market and economic factors, leading to a cautious approach in capital investment and project implementation [1][2][3] Group 1: Fundraising Project Delays - The company raised a net amount of 184 million RMB from a non-public stock issuance in 2020, intended for an 800,000 square meter smart interconnected high-precision circuit board project, which has been delayed multiple times, now expected to complete by December 2025 [1] - The project has seen a total investment of 23 million RMB in 2024, with 65 million RMB of the raised funds still unreturned as of May 2024 [1] - The company’s monetary funds and long-term borrowings totaled 518 million RMB by the end of 2024 [1] Group 2: Market Environment and Business Development - The consumer electronics market saw a decline of 2.37% in 2023, with a projected compound annual growth rate (CAGR) of only 2.25% from 2023 to 2028, significantly lower than the global electronics CAGR of 5.7% [2] - The company’s products are primarily used in consumer electronics and renewable energy sectors, facing intense competition and longer product certification cycles [2][3] - The company has been cautious in capital investments since Q4 2021, slowing down project implementation to mitigate adverse impacts on performance due to market conditions [3] Group 3: Financial Performance - The company reported a revenue of 234.72 million RMB in 2024, down 3.30% year-on-year, with a net loss of 15.44 million RMB, a significant decline of 325.20% compared to the previous year [5] - The company’s performance has been under pressure due to macroeconomic factors, leading to a cautious approach in project funding and execution [5][6] Group 4: Fund Utilization and Compliance - The company has utilized part of the raised funds for temporary working capital, with a total of 160 million RMB returned to the special account by the end of 2023 [10][12] - The company has ensured that the use of funds complies with regulations, with no evidence of misappropriation or violation of fund usage rules [14]

Core Viewpoint - The company intends to use part of the idle raised funds to temporarily supplement its working capital, which is expected to improve the efficiency of fund utilization and reduce financial costs [1][4][6] Fundraising Basic Situation - The company issued 24,824,684 shares at a price of RMB 7.13 per share, raising a total of RMB 176,999,996.92, with all funds received by February 27, 2023 [1] Fund Usage Progress - As of December 31, 2024, the company has invested RMB 9,843.71 million out of the planned RMB 17,700 million, achieving a progress rate of 55.61% [2][3] Temporary Fund Supplement Plan - The company plans to use up to RMB 50 million of idle raised funds for temporary working capital, with a usage period of 12 months from the board's approval date, allowing for rolling use within this limit [3][4] Review Procedures - The board and supervisory committee approved the proposal on July 4, 2025, ensuring that the use of funds does not affect the implementation of investment projects [4][6] Special Opinion - The supervisory committee believes that the temporary use of idle funds will enhance fund efficiency and meet the company's short-term financial needs, aligning with the interests of the company and all shareholders [4][6] Sponsor's Verification Opinion - The sponsor confirms that the company's plan to use idle funds has been approved by the board and supervisory committee, complies with relevant regulations, and does not affect the normal construction of investment projects [6]

Core Viewpoint - The report provides a detailed account of the fundraising activities and the utilization of the raised funds by Xinwanda Electronics Co., Ltd. as of December 31, 2024, confirming compliance with regulatory requirements and reflecting the company's financial management practices [1][2]. Fundraising and Storage - The company raised a total of RMB 1,101.83 million from the issuance of convertible bonds on July 20, 2020, after deducting related expenses [2]. - In addition, RMB 3,881.17 million was raised from the issuance of A-shares on November 10, 2021, after deducting issuance costs [2]. Fund Utilization - As of December 31, 2024, the company completed the "Consumer Lithium-ion Cell Expansion Project," with surplus funds amounting to RMB 130.48 million, representing 11.84% of the total raised from the convertible bonds [3]. - The "Notebook Lithium Battery Module Expansion Project" was also completed, with surplus funds of RMB 59.41 million, accounting for 13.75% of the total raised from the A-share issuance [3]. - The "3C Consumer Lithium-ion Cell Expansion Project" was completed with surplus funds of RMB 205.16 million, which is 14.76% of the total raised from the A-share issuance [4]. Changes in Fund Usage - There were no changes in the use of previously raised funds reported by the company [2][5]. - Surplus funds from completed projects are intended to be permanently supplemented into working capital to enhance operational efficiency and avoid idle funds [3][4]. Project Benefits - The report indicates that the projects funded by the previous fundraising efforts have met their intended goals, with no projects reporting benefits below 20% of the promised returns [5][6]. - The company has committed to using surplus funds for operational needs while ensuring that any outstanding payments will be settled as per contractual agreements [3][4]. Idle Fund Management - The company has utilized idle funds for cash management, with approvals for using up to RMB 550 million from the convertible bond issuance and RMB 230 million from the A-share issuance for cash management purposes [6][7]. - All idle funds used for cash management have been returned to the designated accounts within the approved timeframes [6][7]. Other Issuance Matters - The company issued Global Depositary Receipts (GDRs) on November 14, 2022, raising approximately USD 440 million, with the net proceeds allocated for global business development, R&D enhancement, and working capital [7]. - As of December 31, 2024, all funds raised through GDRs have been fully utilized [7].

Fundraising Overview - The company raised a total of RMB 43,125.00 million by issuing 12.5 million shares at RMB 34.50 per share, with a net amount of RMB 38,182.62 million after deducting issuance costs of RMB 4,942.38 million [1][5] - As of May 31, 2025, the company has utilized RMB 37,747.18 million of the raised funds, with RMB 21,056.91 million invested in projects from April to December 2021 and RMB 5,687.29 million in 2022 [1][5] Fund Management - The company established a fundraising management system to ensure compliance with relevant laws and regulations, including the signing of a tripartite supervision agreement with the underwriter and banks [3][4] - The company changed its underwriter from CITIC Securities to Huatai United Securities, which took over the ongoing supervision responsibilities [4] Fund Usage and Adjustments - The actual investment amount of the embedded computer expansion project was RMB 16,182.62 million after adjustments, with a total of RMB 38,182.62 million allocated for fundraising projects [6][12] - The company has not changed the purpose of the raised funds, nor has it transferred or replaced any projects [7][12] Project Performance - The embedded computer expansion project was completed and put into use by September 2024, with a total investment of RMB 981.42 million transferred to permanent working capital after project completion [7][12] - The company reported that the R&D center's technical transformation project and working capital projects could not be individually assessed for benefits, but they are expected to enhance the company's core competitiveness [12][13] Compliance and Reporting - The company confirmed that the actual use of the raised funds aligns with the disclosures in periodic reports and other information [13] - The board of directors guarantees the authenticity, accuracy, and completeness of the report, assuming legal responsibility for any misrepresentation [13]

Core Points - The company, Nanjing Weisi Medical Technology Co., Ltd., is using its own funds to pay for investment projects and will replace these with raised funds later [1][10] - The total amount raised from the public offering was approximately RMB 1.15 billion, with a net amount of about RMB 1.06 billion after deducting issuance costs [1][10] - The company has adjusted the expected usable status dates for several projects, delaying them from September 2023 to December 2025 due to changes in internal and external environments [3][5][10] Fundraising Overview - The company issued 17,086,667 shares at a price of RMB 67.58 per share, with a face value of RMB 1.00 [1] - The total raised amount was RMB 1,154,716,955.86, with issuance costs of RMB 91,729,995.18 [1] Investment Project Status - The company has planned investments in several projects, including a research center and information technology projects, with total investment commitments adjusted to RMB 106,298.70 million [3][4] - The expected usable status for the "Research Center Construction Project" and "Information Technology Construction Project" has been extended to December 2025 [5][10] Reasons for Using Own Funds - The company needs to comply with regulations regarding salary payments, which require using basic or general deposit accounts rather than the fundraising account [7][8] - To enhance operational efficiency and reduce procurement costs, the company prefers to make bulk purchases using its own funds initially [8][9] Operational Process for Fund Replacement - The finance department will prepare detailed monthly reports on expenditures made with own funds, which will be reviewed and approved before transferring equivalent amounts from the fundraising account [9] - The company will maintain a ledger to track the replacement of funds, ensuring compliance with internal and external regulations [9][10] Impact on Daily Operations - The use of own funds for project payments and subsequent replacement with raised funds is expected to improve efficiency without affecting the normal implementation of investment projects [10] - The board and supervisory committee have approved the process, confirming that it does not harm the interests of the company or its shareholders [10][11]

Core Viewpoint - The company, Jiangsu Longpan Technology Co., Ltd., has initiated a process to enhance the efficiency of its fundraising by opening a margin account for issuing bank acceptance bills and letters of credit, which is expected to lower funding costs and improve overall capital utilization [1][3][4] Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue 82,987,551 shares at a price of RMB 26.51 per share, raising a total of RMB 2,199,999,977.01, with a net amount of RMB 2,175,531,120.83 after deducting issuance costs [1] Specific Operational Process - The company will utilize a margin account to issue bank acceptance bills and letters of credit for payments, following a structured process that includes application, approval, and payment procedures, ensuring compliance with its fundraising management regulations [2] - Funds will be transferred from the fundraising special account to the margin account for the purpose of issuing payment instruments, with interest from the margin account being redirected to the special account upon maturity [2] Impact on the Company - The establishment of the margin account for issuing bank acceptance bills and letters of credit is expected to enhance the overall efficiency of fund usage, reduce costs, and align with the interests of the company and its shareholders, without affecting the normal progress of fundraising projects [3][4] Review Procedures - The board of directors and the supervisory board have approved the proposal to open the margin account, confirming that it meets the operational needs and will not alter the intended use of the raised funds [3][4]

证券代码：603716 证券简称：塞力医疗 公告编号：2025-054债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 关于归还临时补充流动资金的募集资金暨使用部分 闲置募集资金临时补充流动资金的公告 2023年7月27日，经公司第四届董事会第二十九次会议和第四届监事会第十八次会议审议通过，公司使 用9,000万元闲置募集资金临时补充流动资金，主要用于与主营业务相关的生产经营活动，使用期限自 董事会审议批准之日起不超过12个月。2024年7月25日，公司已归还800万元至募集资金专项账户。2025 年6月25日，公司已将剩余8,200万元归还至募集资金专项账户。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2025年6月25日已将前期用于临时补充流动 资金剩余未归还的32,550万元募集资金归还至募集资金专项账户。 ● 为提高募集资金使用效率，减少银行短期借款，降低财务成本，公司拟使用不超过32,500万元闲置募 集资金临时补 ...

证券代码：688082 证券简称：盛美上海 公告编号：2025-040 盛美半导体设备（上海）股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 第二届监事会第二十次会议在中国（上海）自由贸易试验区丹桂路999弄B2栋会 议室举行。本次会议应出席监事3名，实际出席会议的监事3名。全体监事认可本 次会议的通知时间、议案内容等事项，会议的召开符合《中华人民共和国公司法》 《中华人民共和国证券法》等法律法规及《盛美半导体设备（上海）股份有限公 司章程》《盛美半导体设备（上海）股份有限公司监事会议事规则》的相关规定， 合法有效。 会议由监事会主席TRACY DONG LIU女士主持。 二、监事会会议审议情况 （一）审议通过《关于取消监事会、增加董事会人数并修订 <公司章程> 及 其附件的议案》 表决情况：3票赞成，占监事人数的100%；0票弃权；0票反对。 （二）审议通过《关于调整回购股份价格上限的议案》 表决情况：3票赞成，占监事人数的100%；0票弃权；0票反对。 （三）审议通过《关于使用部分 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. reported on the usage of funds raised from its initial public offering, detailing the total amount raised, the current balance, and the allocation of these funds for various projects [1][2][3]. Fundraising Overview - The company raised a total of RMB 400,436,400.00 from the issuance of 40,530,000 shares at RMB 9.88 per share, with a net amount of RMB 358,837,273.38 after deducting issuance costs [1]. - As of March 31, 2025, the remaining balance of the raised funds is RMB 100,390,120.43, which accounts for 27.98% of the net amount raised [8]. Fund Storage Situation - The funds are stored in two bank accounts: - RMB 39,859,763.12 at China Merchants Bank - RMB 60,530,357.31 at Industrial Bank, totaling RMB 100,390,120.43 [2]. Actual Usage of Funds - The company has utilized RMB 27,752.20 million of the raised funds, with the following annual breakdown: - 2021: RMB 1,998.69 million - 2022: RMB 9,931.96 million [9]. - The company has adjusted the allocation of funds, redirecting RMB 10,278.30 million initially intended for vaccine projects to clinical research projects [3]. Temporary Idle Funds Management - The company has engaged in cash management for temporarily idle funds, with a maximum daily balance not exceeding RMB 30 million. The investment returns from cash management in 2021, 2022, and 2023 were RMB 3.4968 million, RMB 7.1798 million, and RMB 8.1850 million, respectively [5][6][7]. Economic Benefits from Investment Projects - The report includes a table detailing the economic benefits realized from the investment projects, although specific figures are not provided in the summary [9][12].